| scholarly article | Q13442814 |
| P50 | author | Lloyd J. Old | Q1866929 |
| Elke Jäger | Q90278495 | ||
| Sacha Gnjatic | Q108791503 | ||
| Julia Karbach | Q108890509 | ||
| P2093 | author name string | Eric Hoffmann | |
| Nasser K Altorki | |||
| Jianda Yuan | |||
| Armin Bender | |||
| Eckhart Weidmann | |||
| Antje Neumann | |||
| Cathy A Ferrara | |||
| P2860 | cites work | Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. | Q33211563 |
| Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting | Q39740168 | ||
| Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. | Q40870242 | ||
| Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. | Q51982834 | ||
| Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide | Q54747960 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 909-918 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival | |
| P478 | volume | 126 |
| Q28709361 | A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy |
| Q36839001 | A tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells |
| Q55136811 | Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. |
| Q28072236 | Adjuvants for peptide-based cancer vaccines |
| Q57688794 | Antigen-specific active immunotherapy for ovarian cancer |
| Q64903075 | Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial. |
| Q34044914 | BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines |
| Q36846646 | CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases |
| Q34753747 | Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications |
| Q37873930 | Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. |
| Q35733359 | Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis |
| Q34613585 | Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer |
| Q35025722 | CpG DNA as a vaccine adjuvant. |
| Q26783826 | CpG Oligonucleotides as Cancer Vaccine Adjuvants |
| Q34235739 | CpG oligodeoxynucleotides enhance the efficacy of adoptive cell transfer using tumor infiltrating lymphocytes by modifying the Th1 polarization and local infiltration of Th17 cells |
| Q38890122 | Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma |
| Q40248942 | Engineering of a self-adjuvanted iTEP-delivered CTL vaccine. |
| Q92861845 | High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence |
| Q51534488 | Immunoglobulin light chain, Blimp-1 and cytochrome P4501B1 peptides as potential vaccines for AL amyloidosis. |
| Q36214731 | Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts |
| Q58553701 | In vivo cancer vaccination: Which dendritic cells to target and how? |
| Q54211947 | Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C). |
| Q35050623 | Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer |
| Q35289145 | Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab |
| Q49192661 | MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice |
| Q47923445 | NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-Lymphocyte Responses in Patients with Myelodysplastic Syndrome |
| Q34546208 | Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants |
| Q34993170 | Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes |
| Q33746041 | Single vs. combination immunotherapeutic strategies for glioma. |
| Q34400322 | TLR-based immune adjuvants. |
| Q38002967 | Targeting epigenetic mediators of gene expression in thoracic malignancies. |
| Q35018021 | The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. |
| Q55034836 | The revival of CpG oligonucleotide-based cancer immunotherapies. |
| Q34067537 | Toll-like receptor agonists: are they good adjuvants? |
| Q37670779 | Tumor lysate-loaded biodegradable microparticles as cancer vaccines |
| Q33690978 | Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity |
| Q40448718 | Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope. |
| Q54647534 | Vaccination with peptides derived from cancer‐testis antigens in combination with CpG‐7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma |
| Q35826767 | Vaccine Potentiation by Combination Adjuvants |
Search more.